Value-based procurement (VBP) is a journey, not a sprint. It’s about putting the patient at the centre of quality affordable healthcare through changes in procurement practices for medical technologies. Patient outcomes drive value and sustainability, not just price. The bigger picture indicates that VBP will create system cost saving through benefitting patients, rather than trying to attain the reverse – a win-win outcome.
Transforming from our price-based sourcing model to a value-based approach requires the sharing of goals and collaborative effort from all stakeholders – doctors, patients, procurement professionals, MedTech professions.
In this AHJ interview William Downey, Customer Solutions Partner ANZ, Johnson & Johnson Medical talks about working with Dr John Rooney, Head of Orthopaedics, St Vincents Hospital, Sydney and Sarah Sweeney, Operational Transformation & Service Innovation Manager, St Vincents Hospital Network, Sydney, on how St Vincents Hospital Network, implemented Value Based Procurement by working with a MedTech supplier and for the ultimately benefit to the patient.
-
New option for management of high-risk soft tissue sarcoma of the limb
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
-
Dental marketing insights from leading authority
Winning the Australian Dental Industry Award for Marketing has had a big impact to Dental Marketing Solutions. As Angus comments in closing, “Receiving the award is social proof to say, well, these guys must know something, because an independent body of their peers has assessed them and said”. He added, “Certainly it’s been good in terms of building our business.”
-
Improved treatment in advanced-stage Hodgkin lymphoma
A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen.
Australian Health Journal spoke with Professor Mark Hertzberg in his role in the ALLG HD10 Clinical Trial and as a former Chair of the Scientific Advisory Committee of the Australasian Leukaemia & Lymphoma Group (ALLG), an organisation involved in improving the treatments and lives of blood cancer patients.
